SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing intense investor backlash following the abrupt cancellation of a major contract with Marvell, which was triggered by the CFO's alleged violation of a confidentiality agreement. The community is sharply divided between those calling for immediate leadership changes to restore credibility and those attempting to buy the dip, citing the company's underlying photonics technology as a reason for long-term optimism.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

High-Trend International Group is trending as a momentum-driven play, with investors closely watching for signs of a short squeeze amid high volatility and active sentiment regarding potential price swings. The community is heavily focused on the stock's thin float and the influence of speculative trading patterns, frequently comparing its aggressive moves to previous market runners.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors digest a major proposed $835 million acquisition of European Lithium, a deal that aims to consolidate 100% ownership of the Tanbreez rare earth project and simplify the company's capital structure. The community is actively debating the potential for a short squeeze amidst high borrow fees and limited share availability, while long-term bulls remain focused on the company's strategic role in Western resource security.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as it hits new record highs, fueled by intense institutional demand and optimistic sentiment surrounding its dominance in the AI infrastructure cycle. Investors are actively debating the sustainability of its multi-trillion-dollar valuation, with bulls pointing to fundamental growth while skeptics monitor for potential signs of overheating.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently under intense scrutiny from the community following the release of Phase 3 results for its CRISPR-based HAE therapy, which met primary and secondary endpoints but has sparked debate over efficacy compared to existing oral alternatives. Investors are actively discussing the stock's high short interest, the potential for a short squeeze, and concerns over future dilution via the company's ATM facility, leaving sentiment sharply divided between those betting on a long-term breakthrough and those wary of clinical and commercial risks.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is experiencing intense volatility and volume-driven interest as investors monitor a tight effective float and speculate on potential buyout scenarios or strategic partnerships. The community remains deeply divided, with bullish participants pointing to recent institutional accumulation and clinical data, while others express skepticism regarding management's communication history and the potential for near-term equity dilution.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as investors digest a massive strategic windfall from its stake in SpaceX and aggressive moves into specialized AI hardware development alongside industry partners. The community remains focused on the company's AI-driven cloud growth and its potential to capture long-term value through its dominant search ecosystem and diversified AI infrastructure investments.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas is seeing heightened activity following reports of the administration evaluating price floor mechanisms for critical minerals, fueling community debate over the companys role as a strategic domestic supply chain asset. While some investors are accumulating shares citing the project's long-term government and corporate backing, others are debating the impact of ongoing project execution risks and broader macro volatility.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is currently trending as investors weigh the potential of a massive stock buyback and dividend hike against persistent concerns regarding smartphone market headwinds and loss of key modem business. The community is actively debating whether the stock represents a deep-value opportunity for AI-driven edge computing or if it remains a value trap due to structural revenue risks.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is currently trending as a prominent infrastructure play in the AI hardware sector, with investors closely watching for earnings-driven volatility after the company's recent strategic collaborations, such as the AMD Helios platform partnership. The community is actively debating the company's valuation relative to its hyperscaler demand, with many focused on whether this quarter will trigger a major breakout or another round of consolidation as it navigates significant institutional interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>In the trial, aimed at evaluating the safety and efficacy of once-weekly Rezzayo, the drug demonstrated a profile comparable with standard antimicrobial regimen in reducing the incidence of invasive fungal infections.</li><li>Rezzayo is already approved in the U.S. for the treatment of candidemia and invasive candidiasis in adults.</li><li>The company estimated that the potential US market opportunity for Rezzayo in preventative care exceeds $2 billion.</li></ul>Shares of CorMedix Therapeutics (CRMD) rose 2% on Monday after the company announced positive results from its late-stage trial evaluating its antifungal drug Rezzayo to prevent invasive fungal diseases (IFDs) in adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).Allogeneic hematopoietic stem cell transplantation is a curative procedure for high-risk blood cancers and marrow diseases, where healthy blood-forming cells from a donor replace a patient's diseased marrow. Patients undergoing the procedure face prolonged periods where their immunity is not strong enough to ward off infections from fungi, including candida, aspergillus, and pneumocystis.Rezzayo is already approved in the U.S. for the treatment of fungal infections, candidemia, and invasive candidiasis in adults. The company estimated that the potential US market opportunity for Rezzayo in preventative care exceeds $2 billion.<h2 class="st-heading-2">Trial Takeaways</h2>In the trial, aimed at evaluating the safety and efficacy of once-weekly Rezzayo, the drug demonstrated a profile comparable with standard antimicrobial regimen in reducing the incidence of invasive fungal infections, the company said. Fungal-free survival at day 90 was 60.7% in the Rezzayo group versus 59.0% in the group that received a standard antimicrobial regimen, it added.Furthermore, the drug was well tolerated with a safety profile showing a favorable benefit/risk profile in the patient population, the company said, while adding that the drug also demonstrated fewer interactions with other drugs and discontinuations due to toxicity.CorMedix now expects to have a meeting with the U.S. Food and Drug Administration in the coming months before submitting an application for the drug for the indication. The company expects to file the application in the second half of 2026 based on the trial results.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CRMD jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels. According to internal data, retail chatter around the stock jumped 1400% over the past day.A Stocktwits user expressed optimism for the stock rising into earnings while adding that “today was great news.”<stembedurl>https://www.stocktwits.com/S2730/message/651521499</stembedurl>Another user expressed muted enthusiasm, opining that the results, though good, are not “transformative.”<stembedurl>https://www.stocktwits.com/ReturnOfEsquire/message/651515352</stembedurl> <a href="https://stocktwits.com/symbol/CRMD">CRMD stock</a> has fallen 17% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sndk-stock-surges-nearly-8-to-hit-fresh-record-high-what-s-behind-the-investor-optimism-april-27/cZBND2dReP8">SNDK Stock Surges Nearly 8% To Hit Fresh Record High – What’s Behind The Investor Optimism?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market 

CorMedix now expects to meet with the U.S. Food and Drug Administration in the coming months. 

Equity

CorMedix now expects to meet with the U.S. Food and Drug Administration in the coming months. 


<ul class="summary-bullets"><li>BTIG added that updated Phase 1 PK/PD data also suggest ORKA-001 could enable once-yearly maintenance dosing, which the firm believes would be a first for any monoclonal antibody.</li><li>The firm raised its price target for Oruka by 94%, to $151 from $78, and maintained a ‘Buy’ rating on the stock.</li><li>Analysts at Guggenheim also hiked their price target for Oruka to $200 from $125, while adding that the company now has the potential to reach a peak of $7 billion in global sales for the psoriasis therapy.</li></ul>Shares of Oruka Therapeutics Inc. (ORKA) were on track for their best single-day gains in more than a month after the company announced interim results from a trial of its moderate-to-severe plaque psoriasis therapy.Oruka Therapeutics announced that 40 of the 63 participants in the EVERLAST-A Phase 2a trial of ORKA-001, a novel, half-life-extended IL-23p19 monoclonal antibody, met the primary endpoint.<a href="https://stocktwits.com/symbol/ORKA">Oruka Therapeutics shares</a> were up more than 20% in Monday’s opening trade.<h2 class="st-heading-2">BTIG Turns Bullish On Oruka</h2>According to TheFly, analysts at BTIG turned bullish on Oruka Therapeutics following the company’s interim trial results. The firm raised its price target for Oruka by 94%, to $151 from $78, and maintained a ‘Buy’ rating on the stock.BTIG added that updated Phase 1 PK/PD data also suggest ORKA-001 could enable once-yearly maintenance dosing, which the firm believes would be a first for any monoclonal antibody.BTIG stated that ORKA-001 has strong potential to become the preferred IL-23 inhibitor if approved, citing best-in-class efficacy and roughly one-fourth the maintenance injection burden of AbbVie’s (ABBV) Skyrizi.Analysts at Guggenheim also hiked their price target for Oruka to $200 from $125, while keeping a ‘Buy’ rating on the stock. The firm believes ORKA-001 has multi-billion-dollar blockbuster potential, adding that Oruka now has the potential to reach a peak of $7 billion in global sales for the psoriasis therapy.<h2 class="st-heading-2">Oruka’s Findings In The Trial</h2>Oruka stated that 64% of the participants in the trial achieved complete skin clearance in the 16th week.The company stated that key secondary endpoints were also strong, with 83% reaching PASI 90 during this period.In the placebo group, one of 21 participants met these endpoints, which it said was consistent with historical psoriasis trials.Oruka stated that cross-trial comparisons suggest ORKA-001 delivers higher skin clearance rates than other IL-23p19 inhibitors and ranks among the best reported in plaque psoriasis across all treatment types.The company stated that it plans to release longer-term EVERLAST-A data in the second half of 2026, including Week 28 results for all patients, along with a 52-week follow-up for a subset. Oruka also added that it will continue to advance the Phase 2b EVERLAST-B trial, with data expected in 2027.PASI refers to the Psoriasis Area and Severity Index. It quantifies the severity and extent of psoriasis symptoms across body regions. PASI 90 refers to a 90% or more improvement. Similarly, PASI 100 denotes a 100% improvement over baseline.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ORKA">Oruka Therapeutics</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels as of this writing.One bullish user believes ORKA stock could reach $200 per share soon.<stembedurl>https://stocktwits.com/Chiefstaff/message/651484000</stembedurl><a href="https://stocktwits.com/symbol/ORKA">ORKA stock</a> is up 172% year-to-date and 716% over the past 12 months. The S&amp;P Biotech ETF (XBI) is up 68% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 42%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/microsoft-loses-exclusive-license-openai-models-taps-anthropic-claude/cZBNAqiRePg">Microsoft Loses Exclusive Access To OpenAI Models In Partnership Reset Ahead Of Q3 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

“We are pleased to have settled our lawsuit with the United States Department of Justice,” the LYV said in a statement as its stock closed higher. 

ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94%

Oruka Therapeutics stated that 64% of the participants in the Phase 2a EVERLAST-A trial of ORKA-001 met the study’s primary endpoint.

<ul class="summary-bullets"><li>Peloton stated that, starting Monday, Spotify Premium subscribers in most countries worldwide can access a curated selection of fitness content.</li><li>This includes strength, pilates, barre, yoga, stretching, meditation, floor cardio and outdoor classes.</li><li>The company stated that the library features sessions in English, Spanish and German, led by a roster of popular instructors, with new classes and formats added regularly.</li></ul>Peloton Interactive Inc. (PTON) on Monday announced a partnership with Spotify Technology SA (SPOT) to bring its fitness content to the music streaming giant’s 290 million subscribers.The partnership between the two companies is part of Spotify’s plans to ramp up the offerings in its new fitness category. This also gives Peloton’s fitness content the exposure to hundreds of millions of Spotify subscribers around the world, helping the company elevate itself from a fitness equipment maker to a fitness content provider.<a href="https://stocktwits.com/symbol/PTON">Peloton shares</a> were up nearly 7% in Monday’s pre-market trade, on track for the biggest gains in this month so far. PTON was among the top trending tickers on the platform at the time of writing.<h2 class="st-heading-2">From Pilates To Yoga And More</h2>Peloton stated that starting Monday, Spotify Premium subscribers across most countries in the world can access a curated selection of Strength, Pilates, Barre, Yoga, Stretching, Meditation, Floor Cardio and Outdoor classes in Spotify’s new Fitness category.The company stated that the library features sessions in English, Spanish and German, led by a roster of popular instructors, with new classes and formats added regularly.“By bringing Peloton directly into our video and audio ecosystem, we are investing in a future where Spotify isn’t just where you spend your time—it’s where you go to build momentum, improve your wellbeing, and get more out of every day,” said Roman Wasenmüller, VP, Global Head of Podcasts, Spotify.Peloton also stated that this partnership underscores its shift toward a more diversified business model.“With this partnership, we are instantly activating a global footprint that makes the magic of Peloton accessible to Spotify Premium subscribers anywhere,” said Peloton’s Chief Commercial Officer, Dion Camp Sanders.Spotify currently has 751 million users and 290 million subscribers in 184 countries.<h2 class="st-heading-2">Trump Tariff Impact On Peloton</h2>According to TheFly, analysts at UBS stated earlier this month that the Section 232 tariff changes will reduce the levies on aluminum that Peloton uses for its equipment to 25% from 50%.The firm maintained its ‘Buy’ rating on PTON stock with a $11 price target, implying an upside of more than 110% from current levels.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/PTON">Peloton</a> trended in the ‘neutral’ territory, with message volumes at ‘high’ levels at the time of writing.One user thinks that Peloton’s market capitalization should be no less than $20 billion, while it is currently hovering around $2.2 billion.<stembedurl>https://stocktwits.com/DORITOBOI/message/651488886</stembedurl><a href="https://stocktwits.com/symbol/PTON">PTON stock</a> is down 16% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/SPOT">SPOT stock</a> is down 11%. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 31% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 43%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ntla-stock-soars-intellia-positive-gene-therapy-trial/cZBNFouRe2C">NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A Peloton bike is displayed at a Dick's Sporting Goods store on May 08, 2024 in Daly City, California. (Photo by Justin Sullivan/Getty Images)

Peloton’s Spotify Deal Opens Doors To 290M Users: PTON Stock On Track For Best Gains This Month

The partnership between the two companies is part of Spotify’s plans to ramp up the offerings in its new fitness category.

<ul class="summary-bullets"><li>The company stated that 62% of the patients in the trial who received lonvo-z were entirely free of HAE attacks during the six-month evaluation period, compared to 11% of patients who received placebo.</li><li>Lonvo-z is a one-time treatment administered in an outpatient setting.</li><li>Intellia Therapeutics also stated that it has initiated a rolling Biologics License Application submission to the U.S. Food and Drug Administration.</li></ul>Shares of Intellia Therapeutics Inc. (NTLA) soared in Monday’s pre-market trade after the company reported positive Phase 3 trial results in its therapy for a rare genetic condition.<a href="https://stocktwits.com/symbol/NTLA">Intellia Therapeutics shares</a> were up more than 9% before the bell on Monday, on track for the biggest gains in this month so far. NTLA was the top trending ticker on the platform at the time of writing.<h2 class="st-heading-2">Rare Genetic Condition Trial Meets All Endpoints</h2>Intellia Therapeutics stated that its Phase 3 trial of lonvoculin ziclumeran (lonvo-z) met the primary and secondary endpoints, with favorable safety and tolerability.The Cambridge, Massachusetts-based biopharmaceutical company evaluated lonvo-z for the treatment of hereditary angioedema (HAE), a rare genetic condition characterized by recurrent, sometimes life-threatening episodes of swelling (angioedema) in different parts of the body. This includes the face, upper airway, abdomen, and extremities due to bradykinin overproduction.The company designed lonvo-z as a one-time treatment that is administered in an outpatient setting. Lonvo-Z is an in vivo CRISPR gene-editing candidate designed to disable the kallikrein B1 (KLKB1) gene, aiming to permanently reduce kallikrein and bradykinin levels.“For those patients who have spent years battling unpredictable breakthrough swelling attacks, anxiety about their next attack or the many burdens associated with chronic prophylactic treatment, lonvo-z represents a potential paradigm shift in treatment,” said Intellia Therapeutics CEO John Leonard.The company stated that 62% of the patients in the trial who received lonvo-z were entirely free of HAE attacks during the six-month evaluation period, compared to 11% of patients who received a placebo.<h2 class="st-heading-2">Intellia Submits Application For FDA Approval</h2>Intellia Therapeutics also stated that it has initiated a rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for approval.It is also preparing for a potential U.S. launch of lonvo-z in the first half of 2027.Intellia Therapeutics stated that it will present additional data at the 2026 European Academy of Allergy and Clinical Immunology Congress in June this year.The company said that one in 50,000 people is estimated to be affected by HAE.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/NTLA">Intellia Therapeutics</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One user stated that gene editing is the future.<stembedurl>https://stocktwits.com/2h2guard/message/651485761</stembedurl>Another bullish user recommended investing now before it is too late for the perfect buying opportunity.<stembedurl>https://stocktwits.com/JuniorStocka/message/651485649</stembedurl><a href="https://stocktwits.com/symbol/NTLA">NTLA stock</a> is up 52% year-to-date and 67% over the past 12 months. The ARK Innovation ETF (ARKK) is up 53% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 65%.The iShares Russell 2000 ETF (IWM) is up 43% during this period, while the Vanguard Small-Cap Growth Index Fund ETF Shares (VBK) is up 36%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/qcom-stock-highest-level-3-months-wall-street-not-bullish-q2-earnings/cZBNZwBRe2M">QCOM Stock On Track To Open At Highest Levels In 3 Months, But Wall Street Is Cautious Ahead Of Q2 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. (Photo by: Spencer Grant/GHI/UCG/Universal Images Group via Getty Images)

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late

Intellia Therapeutics stated that its Phase 3 trial of lonvoguran ziclumeran met the primary and secondary endpoints, with favorable safety and tolerability.

<ul class="summary-bullets"><li>Mizuho stated in its note that AET Pharma is the sole remaining generic challenger that has yet to settle with Harmony Biosciences.</li><li>The firm believes Harmony’s Wakix franchise should be viewed as protected and fully intact through 2030.</li><li>Mizuho also noted that Harmony's lawsuit is a "significant development" and a "major positive" for the company.</li></ul>Shares of Harmony Biosciences Holdings Inc. (HRMY) soared more than 18% in Tuesday’s midday trade after analysts at Mizuho announced that they have learned of a new patent lawsuit filed by the company.According to TheFly, Mizuho analysts stated that Harmony Biosciences has sued AET Pharma for allegedly infringing a patent covering an amorphous formulation of pitolisant.<a href="https://stocktwits.com/symbol/HRMY">Harmony Biosciences shares</a> were up over 14% in Tuesday’s midday trade. Retail sentiment on Stocktwits about the company trended in ‘bullish’ territory, with message volume at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Is The Lawsuit About?</h2>Mizuho stated in its note that AET Pharma is the sole remaining generic challenger that has yet to settle with Harmony Biosciences. The lawsuit covers pitolisant, which was initially developed by Bioprojet and subsequently licensed exclusively by Harmony for the development, manufacture, and commercialization of pitolisant in the U.S.The firm now believes the Harmony Wakix franchise should be considered protected and fully intact through 2030. It also noted that Harmony's lawsuit is a "significant development" and a "major positive" for the company.Mizuho contended that this lawsuit should also remove a major overhang on HRMY stock stemming from concerns that a generic version of pitolisant could be launched before 2030.The firm reiterated its ‘Outperform’ rating on Harmony, with a $50 price target, implying an upside of about 50% from current levels.Koyfin data shows that the average 12-month price target for Harmony is $42, implying an upside of about 27% from current levels. Of the 11 analysts covering the stock, six have either a ‘Strong Buy’ or a ‘Buy’ recommendation, four have a ‘Hold’ rating, and one has a ‘Strong Sell’ recommendation.<h2 class="st-heading-2">What Is Pitolisant Used For?</h2>Pitolisant, originally developed to treat excessive daytime sleepiness and cataplexy in narcolepsy patients, is also being evaluated by Harmony Biosciences for use in individuals with Prader-Willi syndrome.The company also has two pitolisant tablet formulations, namely Pitolisant GR and Pitolisant HD.Harmony is developing Pitolisant GR to enable treatment initiation within the therapeutic dose range. Pitolisant HD is a reformulated version designed to improve how the drug works in the body and to target additional symptoms, such as fatigue, in patients with narcolepsy.Harmony announced in February this year that the U.S. Food and Drug Administration (FDA) approved Wakix (pitolisant) for the treatment of cataplexy in pediatric narcolepsy.“With this approval, clinicians now have the option to prescribe WAKIX to treat excessive daytime sleepiness, cataplexy, or both, in patients 6 years and older with narcolepsy,” said Harmony Biosciences’ Chief Medical and Scientific Officer, Kumar Budur.<a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> is down 10% year-to-date, but up 18% over the past 12 months. The iShares Core S&amp;P Small-Cap ETF (IJR) is up 43% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 51%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/velo-stock-soars-best-gains-4-months-what-is-fueling-rally/cZBI8d9RI6e">VELO Stock Soars 38%, Races Toward Best Single-Day Move In 4 Months — What Is Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say?

Mizuho analysts stated that they have learned that Harmony Biosciences has filed a lawsuit against AET Pharma for allegedly infringing a patent covering an amorphous formulation of pitolisant.

Best-Performing Leveraged ETFs of Last Week

Leveraged ETFs like IONL and HIMZ surged last week on easing Iran war fears, strong earnings and quantum buzz, even as Strait of Hormuz risks persist.

Top-Performing ETFs of Last Week 

ETFs rallied last week on easing Iran war fears, strong earnings and crypto buzz, even as Strait of Hormuz risks linger.

<ul class="summary-bullets"><li>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia cells from natural programmed cell death, making them more vulnerable.</li><li>Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.</li><li>Meanwhile, Sellas’s late-stage trial of its lead candidate GPS in Acute Myeloid Leukemia is advancing toward final analysis.</li></ul>Shares of Sellas Life Sciences Group Inc. (SLS) closed up 6% and edged up 2% after-hours on Friday, garnering heavy retail interest as investors anticipated upcoming data updates on its pipeline at the American Association for Cancer Research.According to Stocktwits platform data, retail chatter increased 36% over the past day, rising from ‘low’ to ‘normal’ levels.Sellas is slated to present preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center. Sellas will make its presentation on April 21.<h2 class="st-heading-2">Pipeline Optimism</h2>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia (AML) cells from natural programmed cell death, making them more vulnerable. Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.“The ability to lower apoptotic threshold in AML cells by suppressing key survival pathways and enhancing potency with repeated exposure further supports the development of SLS009, including in combination regimens,” said Dragan Cicic, Chief Development Officer of SELLAS.Sellas’s lead candidate, GPS, meanwhile, is being evaluated for its potential as a monotherapy and in combination with other therapies to address a broad spectrum of blood malignancies and solid tumor indications.The company’s late-stage trial of GPS in Acute Myeloid Leukemia is advancing toward final analysis. The final analysis is slated for when the company records the 80th patient death in the trial. In December, the company announced that 72 events had been completed and it will announce when the 80th event occurs. With event-driven trials like Sellas’s, the delay highlights longer survival, indicating potential for the therapy.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SLS stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours.A Stocktwits user said that the stock has two near-term catalysts in terms of the upcoming conference and update on the GPS program in AML.<stembedurl>https://www.stocktwits.com/55X_ROI_Q1_2026/message/650652881</stembedurl>Yet another sounded optimistic for the company’s pipeline, highlighting the many designations granted to Sellas’s experimental therapies.<stembedurl>https://www.stocktwits.com/gata2016/message/650649884</stembedurl><a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has nearly quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-on-track-for-best-day-in-nearly-16-months-whats-driving-the-rally/cZJyGq6RIUn">CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy

Sellas is slated to announce preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center.

<ul class="summary-bullets"><li>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma featured in Parade magazine.</li><li>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma.</li><li>New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.</li></ul>Shares of Candel Therapeutics (CADL) jumped 24% on Friday as investors await upcoming clinical data readouts and process positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.The stock is now on track to record its best day since December 2024, if gains hold.<h2 class="st-heading-2">Positive Media Coverage</h2>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma, featured in Parade magazine.Donahue, who was initially given only months to live after her diagnosis, participated in a clinical trial of the company’s investigational viral immunotherapy CAN-3110. Tak described the case as both deeply personal and scientifically meaningful, noting that such outcomes underscore the potential of viral immunotherapies to reshape the tumor microenvironment, activate durable immune responses, and represent a possible turning point in a disease where progress has long been elusive.<h2 class="st-heading-2">Upcoming Catalysts</h2>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma. New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.To add to the momentum, last month, the company announced positive updates for its lead candidate CAN-2409 in patients with advanced non-small cell lung cancer. The company said that extended long-term survival was observed after an additional year of follow-up in an ongoing phase 2a clinical trial, with 50% of 46 patients treated with CAN-2409 surviving beyond 24 months.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CADL stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.A few Stocktwits users expressed optimism for an upcoming buyout or partnership for the company.<stembedurl>https://www.stocktwits.com/drizz/message/650628803</stembedurl><stembedurl>https://www.stocktwits.com/gusm17/message/650618195</stembedurl>Another highlighted the positive press published on Parade, terming it “incredibly positive.”<stembedurl>https://www.stocktwits.com/pyroclast/message/650627286</stembedurl><a href="https://stocktwits.com/symbol/CADL">CADL stock</a> has gained 40% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/omer-stock-on-track-for-best-week-in-nearly-four-months-after-receiving-permanent-reimbursement-code-for-treatment/cZJUzYKRIUj">OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?

Candel stock is rallying on the heels of positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.  

<ul class="summary-bullets"><li>The company said the move reduces administrative hurdles by facilitating easier claims processing for hospitals and clinics.</li><li>Yartemlea is the first and only FDA-approved medicine for hematopoietic stem cell transplant-associated thrombotic microangiopathy.</li><li>The company is now eyeing an approval for the treatment by the European Medicines Agency by mid-2026.</li></ul> Shares of Omeros Corp. (OMER) are on track to close their best week since late December, if gains hold, after the U.S. Centers for Medicare and Medicaid Services assigned a permanent J-code for its recently-approved treatment Yartemlea.Yartemlea is the first and only approved medicine for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The condition can hit people after a stem cell or bone marrow transplant and is a rare, severe, and potentially fatal complication where microscopic blood clots form in small vessels, damaging organs, particularly the kidneys and brain.The company said on Thursday that the J-code will become effective on July 1.<h2 class="st-heading-2">What Is The J-Code?</h2>A J-code is an official “billing sticker” that doctors and hospitals use when they give a patient non-orally administered medications, such as injections, infusions, and chemotherapy. A permanent J-code is designed to simplify billing and speed up reimbursement for a treatment when used by patients covered by Medicare, Medicaid and most commercial insurance plans.Omeros said the move reduces administrative hurdles by facilitating easier claims processing for hospitals and clinics.“For patients with TA-TMA, access to effective treatment without unnecessary delay is critical,” said CEO Gregory A. Demopulos. “The assignment of a permanent, product-specific J-code for YARTEMLEA establishes a clear and consistent reimbursement pathway across payors, reducing administrative burden, supporting faster access for patients, and delivering more predictable reimbursement for providers.”The U.S. Food and Drug Administration approved Yartemlea in December for the treatment of TA-TMA in adults and children aged two years and older. The company is now eyeing an approval for the treatment by the European Medicines Agency by mid-2026.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around OMER stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.A Stocktwits user highlighted the company’s partnership with Danish drugmaker Novo Nordisk (NVO).<stembedurl>https://www.stocktwits.com/resq1/message/650620063</stembedurl>Omeros and Novo entered into a definitive asset purchase and license agreement in October for the candidate drug zaltenibart in clinical development for rare blood and kidney disorders. Under the deal, Omeros is eligible to receive up to $2.1 billion, including milestone payments.Yet another Stocktwits user applauded the J-code as “actually huge” and voiced optimism for it driving commercial acceleration of Yartemlea.<stembedurl>https://www.stocktwits.com/mjk49/message/650580855</stembedurl><a href="https://stocktwits.com/symbol/OMER">OMER stock</a> has gained about 97% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/pbm-stock-on-track-for-best-week-on-over-2-years/cZJUwtIRIUf">PBM Stock On Track For Best Week In Over 2 Years On Hopes For Upcoming Executive Order To Ease Ibogaine Research</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment

Omeros said that the U.S. Centers for Medicare and Medicaid Services assigned a permanent J-code for its recently-approved treatment Yartemlea.

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWM News

IWMiShares Russell 2000 ETF